Clinical Trials Browser

Phase 2 × Withdrawn × blinatumomab × Clear all

NCT03982992 2024-03-12

DLI-TARGET

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04448834 2022-03-02

Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

Phase 2 Withdrawn

Burkitt Lymphoma